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The enzyme thymidylate kinase phosphorylates the substrate thymidine
50-phosphate (dTMP) to form thymidine 50-diphosphate (dTDP), which is
further phosphorylated to dTTP for incorporation into DNA. Ehrlichia
chaffeensis is the etiologic agent of human monocytotropic erlichiosis (HME),
a potentially life-threatening tick-borne infection. HME is endemic in the
United States from the southern states up to the eastern seaboard. HME is
transmitted to humans via the lone star tick Amblyomma americanum. Here, the
2.15 A ˚ resolution crystal structure of thymidylate kinase from E. chaffeensis in
the apo form is presented.
1. Introduction
Thymidylate kinase (TMPK) phosphorylates the substrate thymidine
50-phosphate (dTMP) to form thymidine 50-diphosphate (dTDP). The
overall reaction is as follows:
ATP Mg
2þ þ dTMP  !ADP Mg
2þ þ dTDP:
The newly formed dTDP is subsequently phosphorylated to dTTP
by nucleoside-diphosphate kinase for incorporation into DNA. The
essentiality of dTTP for DNA synthesis makes TMPK a desirable
drug target (Kandeel et al., 2009). There are  60 thymidylate kinase
structures from 19 species currently deposited in the Protein Data
Bank (PDB). The ﬁrst of these protein structures was solved from
herpes simplex virus type I (Wild et al., 1997).
Ehrlichia chaffeensis is an obligate intracellular Gram-negative
coccus bacterium. E. chaffeensis is the etiologic agent of a zoonotic
infection occurring in a deer–tick cycle and is spread via the lone star
tick Amblyomma americanum to the white-tailed deer Odocoileus
virginianus and occasionally to humans. The lone star tick is primarily
found in the southern and southeastern United States. E. chaffeensis
is the causative agent of human monocytotropic ehrlichiosis (HME).
HME was ﬁrst identiﬁed in 1987. Between its discovery and 2005
there were a total of 2396 reported cases of HME, with 471 occurring
in 2005 and a trend of increasing infections from 2001 to 2005. HME
can present as a mild asymptomatic infection. The most common
symptoms, found in over 50% of patients, include fever, headache,
malaise, myalgia and nausea (Dumler et al., 2007). Current treatment
for HME consists of the antimicrobial doxycycline, or rifampicin
when doxycycline cannot be used owing to adverse reactions. Like
many infectious diseases, there is a desire to develop better targeted
drugs to treat HME. The mission of the Seattle Center for Structural
Genomics (SSGCID) is to provide a blueprint for a structure-guided
drug-design efforts.
2. Methods
2.1. Protein expression and purification
The gene encoding thymidylate kinase was ampliﬁed via PCR in a
96-well format using genomic DNA as a template. We used the ligase-
independent cloning (LIC) technique (Aslanidis & de Jong, 1990).
The primers are designed with an additional LIC sequence at the 50
ends that is complementary to theLIC sequence in the plasmid vector(Mehlin et al., 2006; Choi et al., 2011). Puriﬁed PCR products were
again cloned via LIC into the AVA0421 expression vector (Quartley
et al., 2009), which provides a cleavable hexahistidine tag at the
N-terminus of the expressed protein with the sequence MAHHH-
HHHMGTLEAQTQ0GPGS (Choi et al., 2011). The recombinant
plasmids were then transformed into Escherichia coli Rosetta Oxford
strain [BL21*(DE3)-R3-pRARE2] cells for expression testing. The
University of Washington Protein Production Group (UW-PPG)
utilizes recombinant human rhinovirus 3C protease MBP fusion
(His-MBP-3C protease) to cleave the hexahistadine tag (Bryan et al.,
2011). When the tag is cleaved the short GPGS sequence is left on
the N-terminus of the full-length thymidylate kinase recombinant
protein. The gene was assigned the SSGCID clone name
EhchA.01616.a and will further be referred to as EhchA.01616.a/
TMPK.
The transformed cells were tested for expression of soluble protein
in a high-throughput screen and were then moved on to large-scale
expression (Choi et al., 2011). Starter cultures of LB broth with
appropriate antibiotics were grown for  18 h at 310 K. ZYP-5052
auto-induction medium was freshly prepared as per UW-PPG stan-
dard protocols (Choi et al., 2011; Studier, 2005). The bottles were
inoculated with all of the overnight culture. Inoculated bottles were
then placed into a LEX bioreactor (Harbinger, Ontario, Canada).
Cultures were grown for  24 h at 298 K; the temperature was then
reduced to 288 K and the culture was grown for a further  60 h. To
harvest, the culture was centrifuged at 4000g for 20 min at 277 K. Cell
paste was ﬂash-frozen in liquid nitrogen and stored at 193 K.
Frozen recombinant cells were resuspended in a lysis buffer con-
sisting of 25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 0.5%
CHAPS, 30 mM imidazole, 10 mM MgCl2,1 m M tris(2-carboxy-
ethyl)phosphine (TCEP), 250 mgm l
 1 4-(2-aminoethyl)benzene-
sulfonyl ﬂuoride hydrochloride (AEBSF) and 0.025% sodium azide.
The cells were ruptured via sonication, which was followed by incu-
bation with benzonase nuclease (Invitrogen, Carlsbad, California,
USA). The crude lysate was centrifuged at 31 500g and 277 K for
75 min and the supernatant was loaded onto a Nickel HisTrap FF
5 ml column (GE Healthcare, Piscataway, New Jersey, USA) for
immobilized metal-afﬁnity chromatography (IMAC). The column
was washed with 20 column volumes of wash buffer (25 mM HEPES
pH 7.0, 500 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM TCEP
and 0.025% sodium azide). The bound protein was eluted with seven
column volumes of elution buffer (25 mM HEPES pH 7.0, 500 mM
NaCl, 5% glycerol, 1 mM TCEP, 250 mM imidazole and 0.025%
sodium azide). Protein precipitation was observed in the elution
fractions. An additional centrifugation step at 4000g was imple-
mented to remove any insoluble aggregates that had formed. 1 mM
adenosine diphosphate (ADP) and 1 mM MgCl2 were added to the
soluble protein in an attempt to prevent further aggregation.
Cleavage of the N-terminal His tag was accomplished by overnight
277 K dialysis with His-MBP-3C protease in buffer consisting of
25 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM TCEP,
0.025% sodium azide, 1 mM ADP and 1 mM MgCl2. The cleaved
protein was recovered in both the ﬂowthrough and wash fractions ofa
second Ni
2+-afﬁnity chromatography step that also removed the His-
MBP-3C protease, uncleaved protein and cleaved His tag.This IMAC
clariﬁcation step utilized the same buffers as the initial IMAC puri-
ﬁcation. After afﬁnity-tag cleavage, a tag remnant GPGS was left on
the N-terminus of the full-length EhchA.01616.a/TMPK. Centrifu-
gation at 43 000g for 30 min was performed to remove any precipi-
tated protein that had formed during the cleavage/dialysis step. The
soluble cleaved protein was further polished using a HiLoad 26/60
Superdex 75 prep-grade column (GE Healthcare) equilibrated with
25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 2 mM dithio-
threitol (DTT), 0.025% sodium azide, 1 mM ADP and 1 mM MgCl2.
SDS–PAGE analysis was used to determine which fractions to pool.
The puriﬁed protein was concentrated to 24 mg ml
 1 and stored at
193 K.
2.2. Crystallization
Thawed protein was used to set up four sparse-matrix screens,
JCSG+ (Emerald BioStructures, Bainbridge Island, Washington,
USA), Crystal Screen and Index HT (Hampton Research, Aliso
Viejo, California, USA) and PACT (Molecular Dimensions,
Newmarket, Suffolk, UK), following an extended Newman strategy
(Newman et al., 2005). 0.4 ml protein solution was then mixed with
0.4 ml well solution and equilibrated against a 100 ml reservoir using
96-well Compact Jr crystallization plates (Emerald BioSystems).
Crystals suitable for diffraction studies were found in condition G8
from the PACT screen: 100 mM Bis-Tris propane pH 7.5, 200 mM
sodium sulfate, 20% PEG 3350. The crystals were cryoprotected with
an additional 25% ethylene glycol.
2.3. Data collection and structure determination
A diffraction data set was collected on 2 December 2009 on ALS
beamline 5.0.1 at the Berkeley Center for Structural Biology in the
context of the Collaborative Crystallography program using a 3   3
tiled ADSC Q315r detector. 150 images were collected with a
’-slicing of 1  per image. The diffraction data were reduced in space
group P212121 to 2.15 A ˚ resolution with XDS/XSCALE (Kabsch,
2010; Table 1).
The packing density (Matthews, 1968) suggested four molecules
per asymmetric unit, with a VM of 2.24 A ˚ 3 Da
 1 and 45% solvent
content. A search of the PDB for sequence homology yielded
thymidylate kinase from Aquifex aeolicus (PDB entry 2pbr; J. Jeya-
kanthan, S. P. Kanaujia, C. Vasuki Ranjani, K. Sekar, N. Nakagawa,
A. Ebihara, S. Kuramitsu, A. Shinkai, Y. Shiro & S. Yokoyama,
unpublished work) as the closest sequence homolog, with 45%
sequence identity. Molecular replacement was performed with the
CCP4( W i n net al., 2011) program Phaser (McCoy et al., 2007) using
data between 20 and 3.5 A ˚ resolution. The initial search model was
modiﬁed with the CCP4 program CHAINSAW (Stein, 2008) based
on sequence alignment with 2pbr. However, a search with the
modiﬁed monomer A from 2pbr was not successful. A further trun-
cation of the C-terminal residues 137–197 yielded convincing solu-
tions for four monomers. Phases were improved with the CCP4
program Parrot (Cowtan, 2010) including NCS averaging. The CCP4
program Buccaneer (Cowtan, 2006) was then used to extend the
initial model; the improved phases from Parrot were included during
this process. 658 residues were built in 12 separate chains. The Rwork
of 0.385 and Rfree of 0.429 indicated a rather incomplete model. The
structural communications
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Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Wavelength (A ˚ ) 0.9774
Space group P212121
Unit-cell parameters (A ˚ ) a = 39.17, b = 144.82, c = 146.84
Resolution range (A ˚ ) 50–2.15 (2.21–2.15)
Unique reﬂections 46708 (3410)
Multiplicity 5.9 (5.8)
Completeness (%) 100 (99.3)
Rmerge† 0.086 (0.529)
Mean I/ (I) 16.8 (3.7)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.model from Buccaneer was then used for model extension in ARP/
wARP (Langer et al., 2008), which built 633 residues in 18 chains with
signiﬁcantly improved R factors: Rwork = 0.228 and Rfree = 0.324. The
model was then iteratively extended manually using Coot (Emsley et
al., 2010) followed by cycles of reciprocal-space reﬁnement with the
CCP4 program REFMAC5 (Murshudov et al., 2011). The ﬁnal model
could be reﬁned with one TLS group per chain to an Rwork of 0.187
and an Rfree of 0.232 with good stereochemistry (Table 2). The model
was validated with the validation tools in Coot and MolProbity (Chen
et al., 2010). The ﬁnal model extends from residue Pro 2 to Gln200
for chains A and C and from Pro 2 to Met201 for chains B and D.I n
each chain residues 135–150 are too disordered to be modeled and
there is a varying amount of disorder in the four chains between
residues 178 and 189. There are two sets of Ramachandran outliers in
this structure: Arg93 and Phe94 from each chain are located in a loop
between a  -strand and an  -helix. The electron density for these two
residues is well deﬁned. The second set is the peptide bond between
Pro 2 and Gly 1, which are part of the puriﬁcation tag. The four
chains almost superimpose and show good electron density; however,
this peptide bond lies in the allowed Ramachandran region for two
chains and in the disallowed region for the other two chains. One
sulfate molecule from the precipitant could be located in each chain
and some ethylene glycol from the cryoprotectant could be placed.
3. Results and discussion
3.1. Overall EhchA.01616.a/TMPK structure
Full-length EhchA.01616.a/TMPK could be puriﬁed with crystal-
lizable quality. The full-length protein with the afﬁnity-tag remnant
sequence GPGS at the N-terminus crystallized rather readily and a
2.15 A ˚ resolution data set was collected on ALS beamline 5.0.1
without further optimization of crystallization conditions. Despite
high sequence identity (45%) to PDB entry 2pbr, molecular
replacement was not straightforward. A signiﬁcant C-terminal trun-
cation was required for the search model to yield a solution. In
hindsight, this could be explained by a larger structural difference
between EhchA.01616.a/TMPK and 2pbr at the C-terminus
compared with the N-terminus. A signiﬁcant peak in a native
Patterson map (20% height of the origin peak) indicated a pseudo-
translational symmetry, which tends to complicate molecular-
replacement searches.
The model of EhchA.01616.a/TMPK consists of four monomers
per asymmetric unit. Interface analysis with PISA (Krissinel &
Henrick, 1997) supports the presence of two separate dimers (AB and
CD). The buried surface area was  1025 A ˚ 2 per monomer compared
with a surface area of  9000 A ˚ 2 per monomer and the free binding
energy was estimated as G
int =  84 kJ mol
 1. The largest crystal-
packing interface has a buried surface area of  600 A ˚ 2 and can only
be found once in the crystal lattice. Dimers are typically observed for
thymidylate kinases and the dimers of EhchA.01616.a/TMPK have
the same quaternary structure as other TMPKs deposited in the PDB.
Hence, we are conﬁdent that the dimer seen twice in this structure is
the native dimer of EhchA.01616.a/TMPK.
The fold seen for EhchA.01616.a/TMPK is as expected for TMPKs:
a central ﬁve-stranded  -sheet is sandwiched between two  -helices
on one side and ﬁve  -helices on the other (Fig. 1). The four chains
of EhchA.01616.a/TMPK are quite similar and superimpose with
r.m.s.d.s of  0.4–0.5 A ˚ for C
  atoms. An SSM search of the PDB for
structural homologs reveals apo thymidylate kinase from A. aeolicus
(PDB entry 2pbr) as the closest homolog, with r.m.s.d.s of around
1.1 A ˚ and some distinct deviations of the C-termini. The second
closest homolog is the structure of ligand-bound thymidylate kinase
from Thermotoga maritima (PDB entry 3hjn; S. Yoshikawa, N.
Nakagawa, M. Shirouzu, S. Yokoyama & S. Kuramitsu, unpublished
work), with r.m.s.d.s in the range 1.3–1.4 A ˚ .
A sulfate ion could be located in each of the monomers of
EhchA.01616.a/TMPK. We assume that the sulfate ion was provided
by the crystallization buffer, which contained 200 mM sodium sulfate.
The structure of TMPK from A. aeolicus shows a sulfate ion in the
same location (Fig. 2a). This protein was crystallized in the presence
of 50 mM lithium sulfate. The structure of TMPK from T. maritima
(PDB entry 3hjn) was crystallized in complex with adenosine
50-diphosphate (ADP) and thymidine 50-diphosphate. The  -phos-
phate group of ADP in 3hjn superimposes with the sulfate in the
other two structures. The nucleotide-binding pocket is structurally
conserved between the ADP-bound T. maritima structure and the
apo E. chaffeensis structure. Nucleotide binding would only require
subtle structural changes that mostly involve side chains. As the
binding pocket is accessible and is not blocked by the crystal lattice,
it is likely that EhchA.01616.a/TMPK crystals will be soakable with
nucleotides.
3.2. Comparison to human TMPK
EhchA.01616.a/TMPK has only 25% amino-acid sequence identity
to the human TMPK protein. When compared with human TMPK
bound to ADP, TMP and Mg
2+ (PDB entry 1e2f; Ostermann et al.,
2000) there are a few observed structural differences. Most notable
structural communications
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Figure 1
Dimer of EhchA.01616.a/TMPK formed by monomers A and B. The ribbons are
colored by secondary structure. Two sulfate ions are shown as yellow/red sticks.
Table 2
Reﬁnement and model statistics.
Values in parentheses are for the highest of 20 resolution shells.
Resolution range (A ˚ ) 50–2.15 (2.21–2.15)
Rcryst† 0.189 (0.205)
Rfree† 0.232 (0.268)
R.m.s.d. bonds (A ˚ ) 0.014
R.m.s.d. angles ( ) 1.34
Protein atoms 5575
Nonprotein atoms 329
Wilson B factor (A ˚ 2) 26.1
Mean B factor (A ˚ 2) 31.5
Residues in favored region 656 [94%]
Residues in allowed region 22 [3.2%]
Residues in disallowed region 10 [1.5%]
MolProbity score [percentile] 1.61 [96th]
PDB code 3ld9
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using an
equivalent equation with the 5% of the reﬂections that were omitted from the
reﬁnement.are the structural differences near the C-terminus. There is a loop
found in the EhchA.01616.a/TMPK structure that is not observed in
the human protein or PDB entries 2pbr or 3hjn. This loop appears to
be a result of a ﬁve-amino-acid insertion from Tyr189 to Asp193. In
the apo structure this loop is in close proximity to the ATP-binding
site, with the loop oriented away from the binding site. It is unknown
whether there are any conformational changes of the loop on
nucleotide binding for the EhchA.01616.a/TMPK protein. It is also
unknown whether this loop has any biological signiﬁcance or whether
this unique structural feature can be exploited for targeted drug
development.
The P-loop nucleoside-binding motif (GX4GKS/T) found in many
nucleotide-binding proteins is present in both the human and Ehrli-
chia TMPKs (Saraste et al., 1994). Speciﬁcally, the P-loop amino-acid
sequences ofthe human andEhrlichia proteins are GVDRAGKS and
GIDGSGKT, respectively. These motifs both contain an acidic Asp
residue that is uniquely found in TMPKs compared with other
nucleoside monophosphate kinases (Lavie et al., 1998). The human
enzyme is a type I TMPK, in which the Asp15 residue is immediately
followed by a catalytically important arginine residue. The Ehrlichia
protein is instead a type II TMPK, with the Asp9 residue being
followed by a glycine residue (Lavie et al., 1998). The P loops of the
human and Ehrlichia enzymes have no major structural differences.
The P loop is one of three regions known to undergo conformational
changes on substrate binding (Ostermann et al., 2000). Substrate-
bound structures of EhchA.01616.a/TMPK would be needed in order
to understand the conformational changes of the P-loop in compar-
ison to those of the human protein. Given the difference in the
catalytic importance of the P loop between type I and type II TMPKs,
it may be possible to exploit this difference for drug design.
The ﬂexible LID region also undergoes conformational changes
and has catalytic differences between type I and type II TMPKs; the
LID region closes upon ATP binding (Ostermann et al., 2000). The
LID region remains unmodeled in the apo EhchA.01616.a/TMPK
structure. As for the P loop, substrate-bound structures would be
needed to fully compare the EhchA.01616.a/TMPK and human
TMPK LID regions. There is no evidence that the overall structure
of the LID region of EhchA.01616.a/TMPK would be signiﬁcantly
different from that of the human protein. However, there are
signiﬁcant amino-acid differences between Ehrlichia, human and
other type II TMPKs. The catalytic arginine found in the P loop of
type I TMPKs is found in the LID region of type II TMPKs. Typically,
type II TMPKs have several basic residues in the LID region; for
example, E. coli TMPK contains ﬁve basic residues in the region as
opposed to three in the human protein (Lavie et al., 1998). The basic
residues of the E. coli protein consist of Lys148, Arg149, Arg151,
Arg153 and Arg158, with Arg153 assuming thecatalytic role ofArg16
in the P loop of the human TMPK. The Ehrlichia protein only
contains two basic residues in the LID region, Arg141 and Lys144,
with Arg141 presumed to be the catalytic residue. Since we do not
currently have substrate-bound EhchA.01616.a/TMPK structures to
fully compare with the human protein, it is difﬁcult to determine the
ability to target the protein with a novel drug based on structural
differences alone. Based on both the catalytic differences of the P
loop and LID region and amino-acid sequence differences, there is a
possibility of speciﬁcally targeting EhchA.01616.a/TMPK over the
human homologue.
4. Conclusion
This paper describes a puriﬁcation strategy that results in
EhchA.01616.a/TMPK of crystallizable quality. The resulting 2.15 A ˚
resolution crystal structure contained two dimers. While the fold is
conserved within the TMPK family, signiﬁcant changes are seen at the
C-terminus which also have an impact on the molecular-replacement
strategy. It is unknown whether there are biological implications of
the difference in the C-terminus compared with other TMPKs. A
sulfate ion from the crystallant occupies the  -phosphate position of
the ADPobserved in homologous structures. Furthermore, substrate-
structural communications
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Figure 2
Superposition of EhchA.01616.a/TMPK monomer A with (a) thymidylate kinase
from A. aeolicus (2pbr) and (b) thymidylate kinase from T. maritima (3hjn). In each
ﬁgure the EhchA.01616.a structure is shown in the same colours as in Fig. 1, while
the ribbons for TMPK from A. aeolicus and T. maritima are shown in light gray.
Ligands for each structure are shown as coloured stick models. The sulfate ions in
EhchA.01616.a/TMPK and A. aeolicus TMPK superimpose. They also superimpose
with a phosphate of ADP in the T. maritima structure.bound structures of EhchA.01616.a/TMPK would be beneﬁcial to
fully analyze the structural differences between the Ehrlichia and
human proteins. At the time of publication, only nine structures of
proteins from E. chaffeensis have been deposited in the PDB.
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